Hui Yang

Hui Yang

Auto-generated profile, based on publicly available information

Hui Yang

Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School Nanjing University Nanjing China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
HYHui Yang
Hui Yang
WSWei Sun
Wei Sun
YFYan-Nan Fan
Yan-Nan Fan
SLShu-Yi Li
Shu-Yi Li
JYJi-Qiao Yuan
Ji-Qiao Yuan
QHQi Hou
Qi Hou
Perilla frutescens (L.) Britton is a classic herbal plant used widely against asthma in China. But its mechanism of beneficial effect remains undermined. In the study, the antiallergic asthma effects of Perilla leaf extract (PLE) were investigated, and the underlying mechanism was also explored. Results showed that PLE treatment significantly attenuated airway inflammation in OVA‐induced asthma mice, by ameliorating lung pathological changes, inhibiting recruitment of inflammatory cells in lung tissues and bronchoalveolar lavage fluid (BALF), decreasing the production of inflammatory cytokines in the BALF, and reducing the level of immunoglobulin in serum. PLE treatment suppressed inflammatory response in antigen‐induced rat basophilic leukemia 2H3 (RBL‐2H3) cells as well as in OVA‐induced human peripheral blood mononuclear cells (PBMCs). Furthermore, PLE markedly inhibited the expression and phosphorylation of Syk, NF‐κB, PKC, and cPLA2 both in vivo and in vitro. By cotreating with inhibitors (BAY61‐3606, Rottlerin, BAY11‐7082, and arachidonyl trifluoromethyl ketone) in vitro, results revealed that PLE’s antiallergic inflammatory effects were associated with the inhibition of Syk and its downstream signals NF‐κB, PKC, and cPLA2. Collectively, the present results suggested that PLE could attenuate allergic inflammation, and its mechanism might be partly mediated through inhibiting the Syk pathway.

16 October 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HYHui Yang
Hui Yang
JGJing Guan
Jing Guan
PMPei Ma
Pei Ma
YFYannan Fan
Yannan Fan
JBJinye Bai
Jinye Bai
QHQi Hou
Qi Hou
Background. Henoch–Schönlein purpura nephritis (HSPN) is the principal cause of morbidity and mortality in Henoch–Schönlein purpura (HSP). However, there is no absolute consensus for the best management of severe HSPN till now. Qingzixiaoban Granule (QZXB GR), a traditional Chinese medicine formula, has been applied to treat HSP in clinical in China. However, the therapeutic effects and potential mechanism of QZXB GR on HSPN is still unknown.Methods. A Gliadin plus Indian Ink-induced HSPN mice model was established. Renal histopathologic changes and the subcutaneous hemorrhage on left legs were assessed. Hematuria and proteinuria were determined using hemocytometer and bicinchoninic acid assay, respectively. The serum circular immune complex and interleukin-6 were quantified by ELISA. Using blood biochemical analyzer, the renal biochemical parameters, including serum total protein, albumin, creatinine, and blood urea nitrogen, were measured. The deposition of immune complex in renal tissues and the lymphocyte subsets in peripheral blood and spleen was investigated by immunohistochemistry and flow cytometry.Results. QZXB GR treatment significantly ameliorated renal injury in HSPN mice, by attenuating renal histopathological changes, reducing subcutaneous hemorrhage, decreasing proteinuria/hematuria, regulating renal biochemical parameters, and inhibiting the release of serum interleukin-6. Furthermore, QZXB GR treatment significantly decreased the level of serum circular immune complex, decreased immune complex IgA and IgG deposition in renal tissue, and suppressed Th2 immunodeviation.Conclusion. QZXB GR could prevent renal injury in HSPN mice, and its renoprotective mechanism might be exerted partly through suppressing immune complexes deposition and Th2 immune deviation.

15 July 2026 in Food Science & Nutrition
Verified
Journal Article
Open access
YLYanli Liu
Yanli Liu
MQMing Qian
Ming Qian
HYHui Yang
Hui Yang
SQShiyu Qian
Shiyu Qian
DLDepin Li
Depin Li
YLYihai Liu
Yihai Liu
To investigate the potential targets and underlying mechanisms of coptisine in regulating platelet activation and thrombosis by integrating an approach combining network pharmacology and experimental validation. An in vivo carotid artery thrombosis model induced by FeCl 3 ‐mediated endothelial injury was established in mice to evaluate the antithrombotic effects of coptisine. A combination of network pharmacology prediction and both in vivo and in vitro experimental validation was employed to elucidate the antithrombotic mechanisms of coptisine. Molecular docking simulations were performed using AutoDock Vina to assess the binding interactions between coptisine and its targets. The in vitro antiplatelet effects of coptisine were assessed using platelet aggregation assays induced by thrombin, ADP, and collagen, as well as a thrombin‐induced platelet activation model. Administration of coptisine significantly reduced thrombus formation in the mouse model of carotid artery thrombosis. Network pharmacology analysis identified four key genes—NFKB1, PTGS2, STAT1, and ACE—as potential core targets contributing to the antithrombotic effects of coptisine. Functional enrichment analysis further indicated the involvement of these targets in pathways relevant to thrombosis and inflammation. Molecular docking studies demonstrated strong binding affinities between coptisine and the identified targets. Both in vivo and in vitro studies confirmed that coptisine treatment markedly attenuated thrombin‐induced platelet activation, as evidenced by reduced platelet inflammation and decreased levels of platelet granule release. This study demonstrates that coptisine exerts significant protective effects against thrombosis‐related diseases through modulation of the NF‐κB and MAPK signaling pathways.